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Abstract
Background: Primary Ewing’s sarcoma originating in the pericranium is an 
extremely rare disease entity.
Case Description: A 9‑year‑old female patient was admitted to our department 
due to a left temporal subcutaneous mass. The mass was localized under the 
left temporal muscle and attached to the surface of the temporal bone. Head 
computed tomography revealed a mass with bony spicule formation on the temporal 
bone, however, it did not show bone destruction or intracranial invasion. F‑18 
fluorodeoxyglucose positron emission tomography showed no lesions other than the 
mass on the temporal bone. Magnetic resonance imaging showed that the mass was 
located between the temporal bone and the pericranium. The mass was completely 
resected with the underlying temporal bone and the overlying deep layer of temporal 
muscle, and was diagnosed as primary Ewing’s sarcoma. Because the tumor was 
located in the subpericranium, we created a new classification, “pericranial Ewing’s 
sarcoma,” and diagnosed the present tumor as pericranial Ewing’s sarcoma.
Conclusion: We herein present an extremely rare case of primary pericranial 
Ewing’s sarcoma that developed on the temporal bone.
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INTRODUCTION
Ewing’s sarcoma, a small round cell tumor that was first 
described by James Ewing in 1921, is most commonly 
diagnosed in the second decade of life.[7,9] Although it is 
the second most common form of primary bone cancer 
in childhood, the primary involvement of the calvaria is 
rare. Periosteal Ewing’s sarcoma is also rare and has been 
reported to affect the long bones.[4,21] Here, we report a 
case of primary Ewing’s sarcoma originating in a pericranial 
location with mild invasion into the temporal bone.
CASE DESCRIPTION
A 9‑year‑old girl had been well until 2 months before 
admission when she noticed a small subcutaneous 
mass in the left temporal region. The mass thereafter 
rapidly became larger. A skull X‑ray at the first hospital 
showed no bone defects or expansion; however, a skull 
X‑ray with dynamic range compression modification 
showed a sunburst appearance on the left temporal 
bone [Figure 1a]. Computed tomography (CT) of the 
head also showed a sunburst appearance due to bony 
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spicule formation in a soft mass that was attached to 
the surface of the left temporal bone, without osteolysis, 
bone expansion, or cortical destruction [Figure 1b]. She 
was referred to our hospital for further examinations 
and treatment. She was healthy, with no history of 
recent systemic symptoms or relevant medical history. 
A physical examination showed a firm, unmovable, mildly 
tender, and slightly elastic subcutaneous mass measuring 
5 × 5 cm in size in the temporal region with apparently 
normal overlying skin. She had no cervical lymph node 
swelling. Her general, systemic, and neurological statuses 
were normal, as well as her blood examination results. 
F‑18 fluorodeoxyglucose positron emission tomography/
computed tomography (F‑18 FDG PET/CT) detected a 
highly‑labeled extracranial mass lesion on the nonlabeled 
temporal bone without metastasis [Figure 1c]. 
Magnetic resonance imaging (MRI) showed a mass 
lesion between the temporal muscle and the lamina 
externa of the temporal bone without intracranial 
extension. The mass lesion exhibited isointensity 
on T1‑weighted imaging (T1WI) and T2‑weighted 
imaging (T2WI) and was heterogeneously enhanced 
on the postcontrast T1WI [Figure 1d‑f]. Postcontrast 
T1WI showed the enhancement of the outer and inner 
membranous structures that were connected to the 
pericranium [Figure 1e, f; arrows and arrowheads]. For 
the radical removal of the tumor, the soft tumor was 
separated from the temporal muscle along an overlying 
thin membrane that appeared to be the pericranium 
and which likely corresponded to the outer membrane 
on postcontrast T1WI. The tumor was dissected from 
the surface of the temporal bone and removed with the 
deep layer of the temporal muscle. An intraoperative 
histological examination confirmed the margin to 
be negative. The outer surface of the temporal bone 
was slightly irregular, suggesting invasion of the 
tumor from the outside into the bone. The temporal 
bone was also resected with a margin of 1 cm. Bone 
replacement material was used to fill the bone defect, 
and then cranioplasty was performed with absorbable 
plates and screws. The histopathological findings were 
consistent with Ewing’s sarcoma [Figure 2a]. The 
tumor was composed of small round cells that were 
strongly positive for CD99, focally positive for s‑100, 
and negative for cytokeratin (AE1/AE3), desmin, 
myogenin, LCA, and TdT. The tumor was positive 
for EWS‑FLI‑1 translocation. The tumor was mainly 
an extracranial mass that was attached to the outer 
surface of the temporal bone with bone reaction on 
the surface, and with local invasion into the temporal 
bone [Figure 2b‑d]. It infiltrated into some marrow 
cavities under very thin compact bone [Figure 2b‑d]. 
Postoperative postcontrast T1WI showed no residual 
enhancement of the mass lesion. At 24 days after the 
operation, chemotherapy (vincristine, doxorubicin, 
and cyclophosphamide alternating with ifosfamide 
and etoposide [VDC/IE]) was administered. Local 
radiation therapy was administered after the third 
cycle of chemotherapy. She completed her course of 
chemotherapy at 9 months after the operation and is 
currently in complete remission.
Figure 1: Preoperative images. A skull X-ray with dynamic range compression (a), axial computed tomography of the skull (b), F-18 
fluorodeoxyglucose positron emission tomography (c), axial T2-weighted imaging (d), and postcontrast T1-weighted imaging of the axial 
plane (e) and coronal plane (f). Arrows and arrowheads indicate the enhanced outer and inner membranous structures, respectively
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DISCUSSION
In the present case, Ewing’s sarcoma was located 
between the pericranium and the temporal bone. The 
main imaging and histopathological findings were as 
follows. First, the skull X‑ray and CT showed a sunburst 
appearance as a periosteal reaction, without the presence 
of a bone defect. Second, MRI showed two enhanced 
membranous structures that surrounded the tumor and 
were connected to the pericranium. Third, although the 
tumor was mainly located outside the temporal bone, the 
histopathological analysis revealed that it had invaded 
some of the marrow cavities in the temporal bone. These 
findings suggested pericranial Ewing’s sarcoma with mild 
invasion into the membranous bone.
Ewing’s sarcoma, a small round cell tumor, is most 
often diagnosed in the second decade of life and is the 
second most common form of primary bone cancer in 
childhood.[9] Between 1973 and 2004, the annual incidence 
of Ewing’s sarcoma in the United States was 2.93 cases per 
million.[6] In approximately half of the cases, the tumors 
were located in the patients’ extremities.[9] In contrast, the 
primary involvement of the skull only occurred in 1–2% of 
Ewing’s sarcomas.[1,17] Intracranial extension was present 
in the majority of primary calvarial Ewing’s sarcomas; 
extracranial extension was only observed in 8 cases of 
primary calvarial Ewing’s sarcoma.
The periosteal reaction is a rare radiographic appearance 
in primary Ewing’s sarcoma cases that involve the 
bones of the head and neck.[23] Cortical thickening was 
observed in only 8% of the cases, whereas permeative 
changes were recognized in 54% of cases. In contrast, 
pure lytic changes (58%) and honeycombing (21%) 
are more common among these patients; among other 
primary Ewing’s sarcoma patients, pure lytic changes 
and honeycombing occurred in 18.6% and 5.8% of 
cases, respectively. Bone expansion, which occurs in 
25% of the head and neck cases, and cortical violation, 
which occurs in 50% of the cases, are also much more 
frequent than in the general population.[23] Among the 8 
previous cases of primary calvarial Ewing’s sarcoma that 
involved extracranial extension, osteolytic destruction or 
cortical violation was observed in 7 cases; the remaining 
case was a congenital case in which Ewing’s sarcoma 
occurred in the frontonasal area.[2,5,8,11,13,15,16,25] Although 
a sunburst periosteal reaction was observed in the 
present case, osteolytic lesions, honeycomb lesions, bone 
expansion, and cortical violation were not observed on 
the skull X‑ray or CT [Figure 1a, b]. F‑18 FDG PET/
CT showed a strongly labeled tumor on the surface of 
the nonlabeled temporal bone [Figure 1c]. Postcontrast 
T1WI showed enhanced outer and inner membranous 
structures that formed the tumor boundaries and which 
were connected to the pericranium; the structures 
were considered to be the pericranium and a reactive 
attachment of the tumor to the surface of the temporal 
bone, respectively [Figure 1e, f]. A histopathological 
examination showed that there was little destruction of 
the underlying temporal bone with local infiltration of 
the tumor into the marrow cavities [Figure 2b‑d]. These 
imaging and histopathological findings suggested that the 
tumor occurred at a subpericranial location.
Periosteal Ewing’s sarcoma is a rare form of Ewing’s 
sarcoma that particularly affects the femur.[3] Periosteal 
Ewing’s sarcoma is defined as a subperiosteal tumor 
without any medullary involvement. In the long bone, 
the medullary cavity (yellow bone marrow) is covered 
by hard and thick compact bone on which periosteal 
Ewing’s sarcoma may occur. In the present case, the 
temporal bone had marrow cavities in the compact bone 
immediately under the surface [Figure 2b, d] and mild 
invasion into the compact bone resulted in invasion into 
the marrow cavities [Figure 2c]. The present case was 
not considered to meet the criteria for the definition of 
periosteal Ewing’s sarcoma because the tumor involved 
the marrow cavities. However, it is difficult to compare 
the present case with previous cases of periosteal 
Ewing’s sarcoma affecting the long bones because there 
are structural differences between the long bones and 
the membrane bones, for example, the thickness of 
the compact bone (as mentioned above). Because the 
preoperative images and the operative findings indicated 
Figure 2: The histopathological features of the tumor. Hematoxylin 
and eosin staining of the tumor (a) and the outer surface of the 
temporal bone (b-d). The tumor infiltrated some of the marrow 
cavities (black arrows in [b]), but not others (white arrow in [b]). 
The tumor invaded the compact bone (c) and infiltrated the 
marrow cavities under the thin compact bone (d). The black 
arrowheads in (b-d) show the surface of the temporal bone. Scale 
bars: 50 μm (a, c, d); 200 μm (b)
dc
ba
SNI: Unique Case Observations 2016, Vol 7: Suppl 15 - A Supplement to Surgical Neurology International
S447
that the tumor was mainly located in the subpericranial 
region, we created a new classification, “pericranial 
Ewing’s sarcoma,” and diagnosed the present case as 
primary pericranial Ewing’s sarcoma. There is a previous 
report of a case of primary calvarial Ewing’s sarcoma 
attached to the skull in which the tumor was completely 
extracranial.[16] Naidu reported that there was no evidence 
of any communication with the intracranial contents at 
the site of the attachment and only irregularity of the 
outer table of the skull. However, it is difficult to define 
that case as pericranial Ewing’s sarcoma because the CT 
and MRI findings were not provided. To the best of our 
knowledge, the present study represents the first report of 
pericranial Ewing’s sarcoma.
Then, what were the cells of origin in the present case? 
Ewing’s sarcoma expresses the EWS‑FLI‑1 fusion gene, 
which is generated by chromosomal translocation, whereas 
EWS‑FLI‑1 induces cell cycle arrest in normal murine 
and human fibroblasts because of EWS‑FLI‑1‑mediated 
cytotoxicity.[14] This causes difficulty in inducing Ewing’s 
sarcoma, suggesting that the target cells of EWS‑FLI‑1 
might be the cells of a narrow lineage and/or a limited 
differentiation stage.[24] The current view is that the 
disease arises from mesenchymal or neural crest‑derived 
stem or progenitor cells.[12,19,24] The temporal bone 
arises from neural crest cells, which go through an 
epithelial‑to‑mesenchymal transition and migrate away 
from the neuroepithelium.[10] During intramembranous 
ossification, neural crest derived stem or progenitor cells 
will condense and differentiate into osteoprogenitor 
cells, which in turn give rise to osteoblasts, the mature 
bone‑forming cells.[20] Undifferentiated progenitor 
cells remain at the bone periphery, forming the 
pericranium.[20] We, therefore, hypothesize that the cells 
of origin in the present case might be neural crest derived 
stem or progenitor cells in the pericranium. In the cranial 
bone marrow, there are also neural‑crest derived stem 
cells, which might give rise to Ewing’s sarcoma in the 
cranial bone marrow.[22] The periosteal and meningeal 
dura are present on the inner surface of the cranial bone. 
Similar to the pericranium, the dura mater has been 
reported to induce osteogenesis and to have stem cells, 
which suggests that dura mater stem cells might give rise 
to intracranial Ewing’s sarcoma.[18,26]
CONCLUSION
We herein reported the first known case of primary 
pericranial Ewing’s sarcoma which occurred in a 
9‑year‑old girl.
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